新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Quest 10亿美元进行股份回购计划

Quest 10亿美元进行股份回购计划

来源:生物谷 2013-08-24 23:07

2013年8月24日讯 /生物谷BIOON/ --Quest 公司决定投入额外的10亿美元进行股份回购计划,公司实行这一计划希望能够增强持股人的信心。这次增资让公司回购计划的资金总额达到13亿美元。公司CEO表示2013年对于Quest是重要的一年,虽然受困于医疗体系支出减少和检测市场不景气,公司仍及时将旗下的HemoCue检测产品以3亿美元出售,并出售了其唾液检测子公司OralDNA。

公司目前仍处于重组业务的进程中,根据不久前公布的计划,公司将裁员600人。但是Quest公司仍然对其业绩增长充满信心,公司分别收购了Dignity Health的实验室推广业务和Concentra的毒理学业务。公司预计这两笔收购案每年能为公司增加1%到2%的收入。(生物谷Bioon.com)

详细英文报道:

Quest Diagnostics ($DGX) is tossing another $1 billion into its share repurchase program, looking to reaffirm shareholder confidence after repeatedly dampening its revenue expectations.

The scale-up brings Quest's total repurchase war chest to about $1.3 billion, CEO Steve Rusckowski said, and $300 million of the new cash comes from the company's July sale of its stake in the blockbuster hopeful ibrutinib. Quest flipped its share of the Johnson & Johnson ($JNJ) cancer drug to Royalty Pharma for $485 million flat, just days after the molecule won the FDA's coveted "breakthrough" designation.

Coupled with that was Quest's revelation that it now expects full-year sales to come in between 1% and 2% below 2012, a downgrade from the flat revenue it previously projected. The results cratered Quest's stock price about 6% to $58, and the company's shares have charted a rocky path ever since, closing at $58.76 on Tuesday.

Rusckowski has described 2013 as "a building year" for the diagnostics giant, as it grapples with declining Medicare reimbursement and a bearish market for tests in the U.S. But Quest sees a way forward as a leaner operation, over the past year selling off its HemoCue diagnostic products business to Danaher ($DHR) for $300 million and shipping out salivary testing subsidiary OralDNA to Access Genetics for an undisclosed sum.

Quest is still in the midst of its "Invigorate" plan, announced in the fall, under which the company is cutting up to 600 jobs, changing its managerial structure and reorganizing business units in an effort to save $500 million this year.

Despite all the austerity measures, Quest still has an appetite for deals of its own, buying up the lab outreach segment of Dignity Health and Concentra's toxicology business this year, two deals it expects to add 1% to 2% revenue growth per year.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库